BridgeBio Pharma, Inc. entered into an Investment Agreement on July 1, 2026, to issue and sell 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock to Chinotto Investments, LLC and HCRx Investments HoldCo, L.P. for an aggregate price of $933,900,000 at $1,000 per share. The Preferred Stock is convertible into common stock at an initial conversion price of $137.79 per share and carries a 7.00% annual dividend rate. BridgeBio Pharma, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases.
